Sacred Heart Hospital

Summary

Sacred Heart Hospital is a medical facility located in Pensacola, Florida. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Brain Tumor and other specialties. Sacred Heart Hospital is involved with conducting 129 clinical trials across 289 conditions. There are 8 research doctors associated with this hospital, such as Erlyn C. Smith, Rohit Amin, MD, Ranjith B. Dissanayake, and James F. Watkins.

Top PIs

Clinical Trials running at Sacred Heart Hospital

Heart Failure

Brain Tumor

Ovarian Cancer

Testicular cancer

Breast cancer

Acute Lymphoblastic Leukemia

Lung Cancer

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Pulmonary Artery Sensor

for Heart Failure

This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm (Group 3) NYHA III Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class III HF patients, where patients have daily access to PAP data, including a randomized sub-study to evaluate a clinician-directed patient self-management strategy.

Recruiting

1 award

N/A

10 criteria

Maridebart Cafraglutide

for Heart Failure

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Recruiting

1 award

Phase 3

3 criteria

AccuCinch System

for Heart Failure

This trial is testing a new device called the AccuCinch Ventricular Restoration System in patients with a specific type of heart failure. The device helps the heart pump blood more effectively by supporting and reshaping its lower chamber. The study aims to see if this device, combined with standard medical treatment, is safe and effective. The CorCap Cardiac Support Device (CSD) is a predecessor that has shown safety and effectiveness in improving left ventricular structure and function in heart failure patients.

Recruiting

1 award

N/A

9 criteria